SEARCH

SEARCH BY CITATION

References

  • 1
    Currey HLF, Harris J, Mason RM, Woodland J, Beveridge T, Roberts CJ, Vere DW, Dixon ASJ, Davies J, Owen-Smith B: Comparison of azathioprine, cyclophosphamide, and gold in rheumatoid arthritis. Br Med J 3: 763766, 1974
  • 2
    Hamdy H, McKendry RJR, Mierins E, Liver JA: Low-dose methotrexate compared with azathioprine in the treatment of rheumatoid arthritis: a twenty-four-week controlled clinical trial. Arthritis Rheum 30: 361368, 1987
  • 3
    Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, Trentham DE: Efficacy of low-dose methotrexate in rheumatoid arthritis. New Engl J Med 312: 818822, 1985
  • 4
    Williams HJ, Willkens RF, Samuelson CO Jr, Alarcon GS, Guttadauria M, Yarboro C, Polisson RP, Weiner SR, Luggen ME, Billingsley LM, Dahl SL, Egger MJ, Reading JC, Ward JR: Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum 28: 721730, 1985
  • 5
    Anderson PA, West SG, O'Dell JR. Via CS, Claypool RG, Kotzin BL: Weekly pulse methotrexate in rheumatoid arthritis: clinical and immunologic effects in a randomized, double bline study. Ann Intern Med 103: 489496, 1985
  • 6
    Dougados M, Awada H, Amor B: Cyclosporine in rheumatoid arthritis: a double-blind, placebo-controlled study in 52 patients. Ann Rheum Dis 47: 127133, 1988
  • 7
    Tugwell P, Bombardier C, Gent M, Bennett KJ, Bensen WG, Carette S, Chalmers A, Esdaile JM, Klinkhoff AV, Kraag GR, Ludwin D, Roberts RS: Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis. Lancet 335: 10511055, 1990
  • 8
    Bartlett RR, Anagnostopulos H, Zielinski T, Mattar T, Schleyerbach R: Effects of leflunomide on immune responses and models of inflammation. Springer Semin Immunopathol 14: 381394, 1993
  • 9
    Popovic S, Bartlett RR: Disease modifying activity of HWA 486 on the development of SLE in MRL/I mice. Agents Actions 19: 313314, 1986
  • 10
    Bartlett RR, Popovic S, Raiss RX: Development of autoimmunity in MRL/I mice and the effect of drugs on this murine disease. Scand J Rheumatol Suppl 75: S290S299, 1988
  • 11
    Thoenes GH, Sitter T, Langer KH, Bartlett RR, Schleyerbach R: Leflunomide inhibits experimental autoimmune tubulointerstitial nephritis in rats. Int J Immunopharmacol 11: 921929, 1989
  • 12
    Ogawa T, Inazu M, Gotoh K, Hayashi S: Therapeutic effects of leflunomide, a new antirheumatic drug, on glomerulonephritis induced by antibasement membrane antibody in rats. Clin Immunol Immunopathol 61: 103118, 1991
  • 13
    Popovic S, Bartlett RR: The use of the murine chronic graft versus host disease, a model for SLE, for drug discovery. Agents Actions 21: 284286, 1987
  • 14
    Bartlett RR, Dimitrijevic M, Mattar T, Zielinski R, Germann T, Rude E, Thoenes CG, Kuchle CCA, Scholemmer HU, Bremer E, Finnegan A, Schleyerbach R: Leflunomide: a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplant rejection. Agents Actions 32: 1021, 1991
  • 15
    Kuchle CCA, Thoenes GH, Langer KH, Schorlemmer HU, Bartlett RR, Schleyerbach R: Prevention of kidney and skin graft rejection in rats by leflunomide. Transplant Proc 23: 10831086, 1991
  • 16
    Williams JW, Xiao F, Foster PF, Chong A, Sharma S, Bartlett RR, Sankary HN: Immunosuppressive effects of leflunomide in. a cardiac allograft model. Transplant Proc 25: 745746, 1993
  • 17
    Ulrichs K, Kaitschik J, Bartlett RR, Muller-Ruchholz W: Suppression of natural xenophile antibodies with the novel immunosuppressive drug leflunomide. Transplant Proc 24: 718719, 1992
  • 18
    Leflunomide Investigator's Brochure. Wiesbaden, Germany, Hoechst AG, March 1995
  • 19
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31: 315324, 1988
  • 20
    Cooperating Clinics Committee of the American Rheumatism Association: A seven-day variability study of 499 patients with rheumatoid arthritis. Arthritis Rheum 8: 302334, 1965
  • 21
    Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, Furst D, Goldsmith C, Kieszak S, Lightfoot R, Paulus H, Tugwell P, Weinblatt M, Widmark R, Williams HJ, Wolfe F: The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 36: 729740, 1993
  • 22
    Fries JF, Spitz PW, Kraines RG, Holman HR: Measurement of patient outcome in arthritis. Arthritis Rheum 23: 137145, 1980
  • 23
    Kirwan JR, Reeback JS: Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol 25: 206209, 1986
  • 24
    United States Food and Drug Administration: Summary Basis of Approval, Methotrexate: NDA 8085/S028. Washington, DC, United States Department of Health and Human Services, 1988
  • 25
    Paulus HE, Egger MJ, Ward JR, Williams JH, and the Cooperative Systematic Studies of Rheumatic Diseases Group: Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. Arthritis Rheum 33: 477484, 1990
  • 26
    Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, Katz LM, Lightfoot R Jr, Paulus H, Strand V, Tugwell P, Weinblatt M, Williams HJ, Wolfe F, Kieszak S: American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38: 727735, 1995
  • 27
    Rozman B, Domljan Z, Popovic M, Mladenovic V, Mihajlovic D, Jajic I, Zivkovic M, Low-Friedrich I, Oed C, Seifert H, Strand V: Long term administration of leflunomide to patients with rheumatoid arthritis (abstract). Arthritis Rheum 37 (Suppl 9): S339, 1994
  • 28
    Tugwell P, Bennett K, Gent M: Methotrexate in rheumatoid arthritis. Ann Intern Med 107: 358366, 1987
  • 29
    Pullar T, Hunter JA, Capell HA: Sulphasalazine in rheumatoid arthritis: a double-blind comparison of sulphasalazine with placebo and sodium aurothiomalate. Br Med J 287: 11021104, 1983
  • 30
    Pinals RS, Kaplan SB, Lawson JG, Hepburn B: Sulfasalazine in rheumatoid arthritis: a double-blind, placebo-controlled trial. Arthritis Rheum 29: 14271434, 1986
  • 31
    Williams HJ, Ward JR, Dahl SL, Clegg DO, Willkens RF, Oglesby T, Weisman MH, Schlegel S, Michaels RM, Luggen ME, Polisson RP, Singer JZ, Kantor SM, Shiroky JB, Small RE, Gomez MI, Reading JC, Egger MJ: A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis. Arthritis Rheum 31: 702713, 1988
  • 32
    Ward JR, Williams HJ, Egger MJ, Reading JC, Boyce E, Altz-Smith M, Samuelson CO Jr, Willkens RF, Solsky MA, Hayes SP, Blocka KL, Weinstein A, Meenen RF, Guttadauria M, Kaplan SB, Klippel J: Comparison of auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum 26: 13031315, 1983
  • 33
    Olsen NJ, Cush JJ, Lipsky PE, St. Clair EW, Matteson E, Cannon G, McCune WJ, Strand V, Lorenz T: Multicenter trial of an anti-CD5 immunoconjugate in rheumatoid arthritis (abstract). Arthritis Rheum 37 (Suppl 9): S295, 1994
  • 34
    Kremer JM, Alarcón GS, Lightfoot RW Jr, Willkens RF, Furst DE, Williams HJ, Dent PB, Weinblatt ME: Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity. Arthritis Rheum 37: 316328, 1994